Business Overview: Zeo ScientifiX, Inc. (OTC: ZEOX)

---

Executive Summary

Zeo ScientifiX, Inc., headquartered in Davie, Florida, is a clinical-stage biopharmaceutical company that develops and sells biological therapeutics derived from birth tissue (amniotic fluid) and from a patient's own blood, marketed to physicians and clinics for use in regenerative and degenerative-disease treatment. The company has gone through several identities since its 2011 incorporation as Bespoke Tricycles Inc. in Nevada — becoming Biotech Products Services and Research, Inc. in 2015, then Organicell Regenerative Medicine, Inc. in 2018, and finally Zeo ScientifiX, Inc. in February 2024.

Its principal commercial product is Zofin™ (also marketed as Organicell™ Flow), an amniotic-fluid-derived biologic, alongside Patient Pure X™ (PPX™), an autologous (patient's-own-blood) product, and a broader RAAM portfolio of birth-tissue-derived products. In June 2025 the company acquired BioLumina, LLC, adding topical aesthetic products (including the DAY ZERO and hair-growth-serum trademarks) to diversify beyond its core clinical biologics.

Why it matters: Zeo ScientifiX sits at the center of one of biotech's most legally contested frontiers — unapproved, cash-pay regenerative biologics sold directly to providers outside the traditional FDA drug-approval pathway. Florida's SB 1768 stem-cell law, effective July 1, 2025, is explicitly cited by management as a new state-level tailwind for demand, even as the company operates with a going-concern qualification, an accumulated deficit of roughly $67.7 million, and ongoing uncertainty about how regulators will ultimately classify its core products.

---

1. Core Business Model & How They Work

Zeo ScientifiX manufactures biologic products from birth tissue and autologous blood sources and sells them directly to physicians and clinics ("Providers") who administer them to patients on a cash-pay basis, bypassing traditional insurance reimbursement.

 [Raw material sourcing:    [Processing into biologic    [Sale to Providers       [Provider administers
  donated birth tissue /     products: Zofin (amniotic    (doctors, clinics)        product to patient;
  patient's own blood]  -->  fluid-derived), PPX       --> via 5 in-house sales --> patient pays cash,
                              (autologous), RAAM             reps + independent        no insurance
                              portfolio]                     distributors]             reimbursement]

                  \--> BioLumina topical aesthetic line (acquired June 2025)
                       sold through a separate consumer/aesthetic channel

Because the products are sold as cash-pay offerings to providers rather than reimbursed through insurance, Zeo ScientifiX's growth is tied directly to providers' willingness to stock and use its products and to patients' willingness to pay out-of-pocket — a demand dynamic state regulation can meaningfully shift, as with Florida's new stem-cell statute.

---

2. Business Segments

Zeo ScientifiX is run as a single operating business — the development, manufacture, and sale of regenerative biologic and aesthetic products — and does not report separate reportable segments in its 10-K. The June 2025 BioLumina acquisition added a new product line (topical aesthetics) rather than a distinct reporting segment.

---

3. Key Offerings

---

4. Competitive Landscape

The 10-K names an unusually long list of direct competitors, reflecting how fragmented and crowded the birth-tissue/regenerative-biologics space has become:

• Allogeneic (donor-tissue-derived) competitors: Kimera Labs, Frontier Biologics, Platinum Biologics, Benev Company, Exocel Bio, Re-gen Active Lab, Neobiosis, MiMedix Group, Invitrx Therapeutics, DermaSciences, Signature Biologics, Direct Biologics, and Vitti Labs — all competing for the same provider relationships with similar birth-tissue-derived products.
• Autologous-segment competitors: Regenexx is named as one of the largest players focused on products made from the patient's own blood/tissue, directly competing with Zeo ScientifiX's PPX line.
• Litigation-driven competitive friction: ongoing disputes with BioXtek (a joint-venture dispute filed December 2025) and Exotropin (a sales-agreement dispute) illustrate how contested distributor and partner relationships are in this space.

Zeo ScientifiX's differentiation rests on having both an allogeneic product (Zofin) and an autologous product (PPX) plus issued patents, giving it a broader and somewhat more defensible product mix than single-product competitors, but it remains a small player among more than a dozen named rivals chasing the same providers.

---

5. Strategic Strengths & Risks

Strengths / Moat Sources:

• Issued U.S. patents on nanoparticle and PPX technologies — a real, if narrow, intellectual-property moat in a space where most competitors sell similar tissue-derived products without comparable IP protection.
• Dual-platform product line (allogeneic Zofin + autologous PPX) gives providers more reasons to source multiple products from one supplier rather than switching between single-product vendors.
• Regulatory tailwind: Florida's SB 1768 stem-cell law (effective July 1, 2025) is a state-level demand driver management is actively counting on.
• IND/emergency IND approvals for Zofin-related protocols provide some regulatory validation relative to peers operating with no FDA engagement at all.

Risks:

• Going-concern doubt: auditors have expressed substantial doubt about the company's ability to continue as a going concern, with an accumulated deficit of $67.7 million and a stockholders' deficit of $1.4 million as of FY2025.
• Unresolved FDA classification risk: the company has not obtained a formal FDA opinion on whether its tissue products require HCT/P treatment or a full Biologics License Application (BLA); regulatory reclassification could force a halt to current commercial sales.
• Active litigation with BioXtek and Exotropin creates legal cost and distraction risk, and potential loss of distribution relationships.
• Intense, crowded competition: more than a dozen named rivals compete for the same provider base, limiting pricing power and making customer retention difficult.
• Small scale and thin liquidity: cash of just $221,000 at FY2025 year-end, down from $657,000 a year earlier, against ongoing net losses of $5.5 million.
• Raw material/supplier dependence: reliance on third-party suppliers for birth-tissue raw materials introduces supply continuity risk.

---

6. Financial Overview

---

7. Summary Conclusion

Zeo ScientifiX is a genuine, revenue-generating biopharmaceutical operator selling regenerative biologic products — Zofin, PPX, and the RAAM portfolio — directly to physicians on a cash-pay basis, supplemented by a newly acquired aesthetics line. Its dual allogeneic/autologous product platform and issued patents give it some real differentiation in an unusually crowded field of more than a dozen named competitors, and a new Florida regulatory tailwind gives management a credible near-term growth catalyst.

That said, the company remains financially fragile — a going-concern qualification, thin cash reserves, an ever-growing accumulated deficit, and unresolved FDA classification risk for its core products all weigh heavily against the business. Active litigation with two counterparties adds further uncertainty. This is a small, high-risk, high-margin niche biologics business whose long-term viability depends on favorable regulatory treatment, successful integration of its new aesthetics line, and an eventual path to sustained profitability that it has not yet achieved.